---
title: "Next-generation antibody therapeutics in cancer: ADCs and bispecific antibodies in hematologic and"
id: "pubmed-42711696"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42711696"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42711696/"
doi: "10.1186/s13045-026-01843-1"
published_at: "2026-09-09T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Next-generation antibody therapeutics in cancer: ADCs and bispecific antibodies in hematologic and
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42711696
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42711696/)
- **DOI:** [10.1186/s13045-026-01843-1](https://doi.org/10.1186%2Fs13045-026-01843-1)
- **Published At:** 2026-09-09T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The oncology therapeutic landscape is shifting due to advances in **antibody‑drug conjugates (ADCs)** and **bispecific antibodies (bsAbs)** across hematologic malignancies and solid tumors. These platforms are delivering meaningful clinical activity in refractory settings. - ADCs have expanded treatable populations; notably, trastuzumab deruxtecan redefined care for **HER2‑low** breast cancer and demonstrated intracranial activity, extending the concept of targetable HER2 expression. - New ADC targets in clinical development include **TROP2**, **CLDN18.2**, **B7‑H3**, and **HER3**, and there is progress toward bispecific ADC constructs. - T‑cell‑engaging bsAbs have produced deep, durable responses in heavily pretreated hematologic cancers: **CD20×CD3** for B‑cell lymphomas; **BCMA×CD3** and **GPRC5D×CD3** for multiple myeloma; and **CD19×CD3** for acute lymphoblastic leukemia. - In solid tumors, bsAbs targeting **EGFR‑MET** and **DLL3** have shown clinically validated efficacy; **tarlatamab** (DLL3‑directed) received regulatory approval for a historically refractory indication. - Persisting challenges include management of distinct toxicity profiles, antigen escape and T‑cell exhaustion as resistance mechanisms, and the lack of validated predictive biomarkers to guide patient selection and sequencing. - Optimal sequencing among ADCs, bsAbs, and CAR‑T therapy remains largely empirical; clinical decision pathways are not yet standardized. - Next‑generation approaches — including bispecific ADCs, probody‑drug conjugates, and immune‑stimulating antibody conjugates — alongside combinations with immunotherapy aim to improve therapeutic index and overcome resistance. - The review synthesizes pivotal clinical data and highlights unresolved questions, proposing a roadmap to translate antibody‑based innovations into precision oncology.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42711696/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42711696%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42711696/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42711696/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42711696/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42711696/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42711696/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42711696%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42711696%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42711696/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42711696/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42711696/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42711696/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42711696/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42711696/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42711696/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42711696/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42711696/#similar) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42711696/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42711696/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42711696/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42711696/#substances) Title & authors Abstract Conflict of interest statement Similar articles References Publication types MeSH terms Substances Review J Hematol Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Hematol+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Hematol+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) . 2026 Sep 9;19(1):76. doi: 10.1186/s13045-026-01843-1. # Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors [Jiacheng Lou](https://pubmed.ncbi.nlm.nih.gov/?term=Lou+J&cauthor_id=42711696)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42711696/#full-view-affiliation-1 "Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, China. loujiacheng1986@foxmail.com."), [Yizhu Lyu](https://pubmed.ncbi.nlm.nih.gov/?term=Lyu+Y&cauthor_id=42711696)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42711696/#full-view-affiliation-2 "Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China. lvyizhu890226@126.com.") Affiliations Expand ### Affiliations * 1 Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, China. loujiacheng1986@foxmail.com. * 2 Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China. lvyizhu890226@126.com. * PMID: **42711696** * DOI: [ 10.1186/s13045-026-01843-1 ](https://doi.org/10.1186/s13045-026-01843-1) Item in Clipboard Review # Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors Jiacheng Lou et al. J Hematol Oncol. 2026. Show details Display options Display options Format Abstract PubMed PMID J Hematol Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Hematol+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Hematol+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) . 2026 Sep 9;19(1):76. doi: 10.1186/s13045-026-01843-1. ### Authors [Jiacheng Lou](https://pubmed.ncbi.nlm.nih.gov/?term=Lou+J&cauthor_id=42711696)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42711696/#short-view-affiliation-1 "Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, China. loujiacheng1986@foxmail.com."), [Yizhu Lyu](https://pubmed.ncbi.nlm.nih.gov/?term=Lyu+Y&cauthor_id=42711696)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42711696/#short-view-affiliation-2 "Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China. lvyizhu890226@126.com.") ### Affiliations * 1 Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, China. loujiacheng1986@foxmail.com. * 2 Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China. lvyizhu890226@126.com. * PMID: **42711696** * DOI: [ 10.1186/s13045-026-01843-1 ](https://doi.org/10.1186/s13045-026-01843-1) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract The therapeutic paradigm in oncology is undergoing a profound transformation driven by antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs). This review comprehensively summarizes recent clinical advances of these platforms across both hematologic malignancies and solid tumors. ADCs such as trastuzumab deruxtecan have expanded the concept of targetable HER2 expression, demonstrating meaningful intracranial activity and redefining standards of care in HER2-low breast cancer and beyond. The landscape continues to broaden with novel ADC targets (TROP2, CLDN18.2, B7-H3, HER3) and bispecific ADC constructs. Concurrently, T‑cell-engaging bsAbs-CD20×CD3 in B‑cell lymphomas, BCMA×CD3 and GPRC5D×CD3 in multiple myeloma, and CD19×CD3 in acute lymphoblastic leukemia-have achieved deep and durable responses in heavily pretreated populations. In solid tumors, EGFR‑MET and DLL3‑targeted bsAbs have delivered clinically validated efficacy in historically refractory settings, including regulatory approval of tarlatamab. Despite these successes, critical challenges persist, including the management of unique toxicity profiles, the emergence of resistance via antigen escape and T‑cell exhaustion, and the absence of validated predictive biomarkers. Optimal sequencing of these agents with one another and with chimeric antigen receptor T‑cell therapy remains largely empirical. Next‑generation strategies-bispecific ADCs, probody‑drug conjugates, and immune‑stimulating antibody conjugates-combined with immunotherapy partnerships hold promise for overcoming resistance and improving therapeutic indices. By distilling pivotal clinical data and highlighting unresolved questions, this review provides a roadmap for translating antibody‑based innovations into precision oncology. **Keywords:** Antibody–drug conjugate; Bispecific antibody; Hematologic malignancy; Immunotherapy; Solid tumor. © 2026. The Author(s). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. ## Similar articles * [ Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. ](https://pubmed.ncbi.nlm.nih.gov/42329247/) Awadallah C, Zayad A.Awadallah C, et al.Oncology (Williston Park). 2026 May 29;40(4). doi: 10.46883/2026.25921166.Oncology (Williston Park). 2026.PMID: 42329247Review. * [ From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies. ](https://pubmed.ncbi.nlm.nih.gov/40508128/) Amoozgar B, Bangolo A, Habibi M, Cho C, Goy A.Amoozgar B, et al.Int J Mol Sci. 2025 Jun 1;26(11):5319. doi: 10.3390/ijms26115319.Int J Mol Sci. 2025.PMID: 40508128Free PMC article.Review. * [ Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action. ](https://pubmed.ncbi.nlm.nih.gov/41630133/) Paz-Manrique R, Pinto JA, Gomez Moreno HL.Paz-Manrique R, et al.Hematol Oncol Stem Cell Ther. 2025 Oct-Dec 01;18(4):133-139. doi: 10.4103/hemoncstem.HEMONCSTEM-D-24-00042. Epub 2026 Feb 2.Hematol Oncol Stem Cell Ther. 2025.PMID: 41630133Review. * [ Antibody-Drug Conjugates and Beyond: Next-Generation Targeted Therapies for Breast Cancer. ](https://pubmed.ncbi.nlm.nih.gov/41463194/) Wali AF, El-Tanani M, Talath S, Rabbani SA, Rangraze IR, Satyam SM, Avagimyan A, Hoffmann K, Ilias I, Ispas S, Viviana M, Paczkowska A, Rizzo M.Wali AF, et al.Cancers (Basel). 2025 Dec 10;17(24):3943. doi: 10.3390/cancers17243943.Cancers (Basel). 2025.PMID: 41463194Free PMC article.Review. * [ Antibody-drug conjugates in lung cancer: current landscape and future perspectives. ](https://pubmed.ncbi.nlm.nih.gov/41222552/) Chen X, Zhou C.Chen X, et al.Curr Opin Oncol. 2026 Jan 1;38(1):71-82. doi: 10.1097/CCO.0000000000001200. Epub 2025 Oct 22.Curr Opin Oncol. 2026.PMID: 41222552Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42711696) ## References 1. 1. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. . - [DOI](https://doi.org/10.1038/s41392-022-00947-7) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35318309/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/8941077/) 2. 1. Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641–61. . - [DOI](https://doi.org/10.1038/s41573-023-00709-2) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/37308581/) 3. 1. Colombo R, Tarantino P, Rich JR, de LoRusso PM. The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discov. 2024;14:2089–108. . - [DOI](https://doi.org/10.1158/2159-8290.cd-24-0708) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/39439290/) 4. 1. Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301–19. . - [DOI](https://doi.org/10.1038/s41573-024-00896-6) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/38448606/) 5. 1. Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539–60. . - [DOI](https://doi.org/10.1038/s41571-024-00905-y) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/38822215/) Show all 170 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Antibodies, Bispecific* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Bispecific%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Bispecific) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Antineoplastic Agents, Immunological* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Immunological%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents%2C+Immunological) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Hematologic Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematologic+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hematologic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Hematologic Neoplasms* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematologic+Neoplasms%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hematologic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Immunoconjugates* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoconjugates) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Neoplasms* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) ## Substances * Antibodies, Bispecific Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Bispecific%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antibodies%2C+Bispecific%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Immunoconjugates Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Immunoconjugates%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42711696/) * Antineoplastic Agents, Immunological Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Immunological%22%5Bnm%5D&sort=date&sort_order=desc) * [ Se
## Related Clinical Research

- [Normalized membrane ratio of TROP2 predicts response to datopotamab deruxtecan in NSCLC](https://medichelpline.com/clinical-feed/nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with.md)
- [ERBB2 Activating Mutations Increase Trastuzumab Deruxtecan Activity in HER2-Nonamplified mBC](https://medichelpline.com/clinical-feed/pubmed-42714867.md) (DOI: 10.1158/1078-0432.CCR-26-0198)
- [Phase-space Geometry of NF-κB Networks Modulates Phenotypic Plasticity in Breast Cancer](https://medichelpline.com/clinical-feed/pubmed-43037823.md) (DOI: 10.1007/s11538-026-01797-y)
- [HER2-targeted antibody–molecular glue conjugate drives selective cyclin K degradation](https://medichelpline.com/clinical-feed/biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k.md)
- [5-year iDFS After PET-Guided Chemotherapy De-escalation in HER2-Positive Early Breast Cancer (PHER](https://medichelpline.com/clinical-feed/nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.